Apellis Pharmaceuticals, Inc.
APLSDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Apellis Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Apellis Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wheeler Craig A | Director | 0 | May 14, 2026 | 2 |
| Dolsten Mikael | Director | 0 | May 14, 2026 | 2 |
| Machiels Alec | Director | 0 | May 14, 2026 | 2 |
| Chan Gerald | Director | 0 | May 14, 2026 | 2 |
| Watson David O. | General Counsel | 0 | May 14, 2026 | 9 |
| Deschatelets Pascal | Chief Scientific Officer | 0 | May 14, 2026 | 5 |
| Francois Cedric | Chief Executive Officer | 0 | May 14, 2026 | 7 |
| Sullivan Timothy Eugene | Chief Financial Officer | 0 | May 14, 2026 | 7 |
| O'Brien Stephanie Monaghan | Director | 0 | May 14, 2026 | 3 |
| Dunlop A. Sinclair | Director | 0 | May 14, 2026 | 4 |
| Fonteyne Paul R. | Director | 0 | May 14, 2026 | 2 |
| Nicholson Nur | Chief Technical Officer | 0 | May 14, 2026 | 5 |
| Chopas James George | VP/Chief Accounting Officer | 0 | May 14, 2026 | 5 |
| DeLong Mark Jeffrey | Chief Business & Strat Officer | 0 | May 14, 2026 | 6 |
| Baumal Caroline | Chief Medical Officer | 0 | May 14, 2026 | 5 |
| Walbert Keli | Director | 0 | May 14, 2026 | 2 |
| Boucher Kelley | Chief People Officer | 0 | May 14, 2026 | 2 |
| Meltzer Leslie | Chief Research and Development | 0 | May 14, 2026 | 2 |
| Townsend Adam J. | Chief Commercial Officer | 84,050 | Jan 30, 2025 | 0 |
| Lewis Karen | Chief People Officer | 70,251 | Jan 30, 2025 | 0 |
| Eisele Jeffrey | Chief Development Officer | 55,312 | Jan 30, 2025 | 0 |
| Scheibler Lukas | Chief Research Officer | 68,299 | Dec 5, 2023 | 0 |
| Brown Victoria L. | Program Team Lead | 23,556 | Jan 24, 2023 | 0 |
| Grossi Federico | Chief Medical Officer | 94,884 | Jan 9, 2023 | 0 |
| Morningside Venture Investments Ltd | 10% Owner | 12,806,342 | Nov 18, 2021 | 0 |
| Perry Nicole D | Vice President - Accounting | 4,847 | Aug 3, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2024 (view filing) | Sep 3 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −550 | $39.49 | −$21.7K | −1.4%38.3K after | |
| Sep 17, 2024 (view filing) | Sep 16 | 1 day | Dunlop A. SinclairDirector | SSale | −37.0K | $36.23 | −$1.34M | −27.0%100.0K after | 2 lots |
| Sep 17, 2024 (view filing) | Sep 16 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −192 | $36.21 | −$6.95K | −0.5%38.1K after | |
| Dec 13, 2024 (view filing) | Dec 11 | 2 days | Watson David O.General Counsel | SSale | −5.00K | $34.24 | −$171.2K | −4.2%112.7K after | |
| Dec 27, 2024 (view filing) | Dec 23 | 4 days | Eisele JeffreyChief Development Officer | SSale | −63 | $33.09 | −$2.08K | −0.1%57.1K after | |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Baumal CarolineChief Medical Officer | SSale | −2.82K | $33.81 | −$95.2K | −4.8%55.6K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −783 | $28.70 | −$22.5K | −2.1%37.4K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −1.60K | $28.70 | −$45.9K | −2.6%58.8K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −2.29K | $28.70 | −$65.7K | −0.2%1.14M after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Eisele JeffreyChief Development Officer | SSale | −264 | $28.70 | −$7.58K | −0.5%56.9K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Francois CedricChief Executive Officer | SSale | −6.25K | $28.70 | −$179.3K | −2.0%307.4K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Lewis KarenChief People Officer | SSale | −1.60K | $28.70 | −$45.9K | −3.4%45.1K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Nicholson NurChief Technical Officer | SSale | −2.63K | $28.70 | −$75.5K | −4.6%54.2K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Sullivan Timothy EugeneChief Financial Officer | SSale | −2.17K | $28.70 | −$62.3K | −2.4%88.1K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −2.69K | $28.70 | −$77.1K | −2.9%90.3K after | |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Watson David O.General Counsel | SSale | −4.96K | $28.70 | −$142.5K | −4.4%107.8K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Baumal CarolineChief Medical Officer | SSale | −1.85K | $29.96 | −$55.5K | −3.3%53.7K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −715 | $29.96 | −$21.4K | −1.9%36.6K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −1.24K | $29.96 | −$37.0K | −2.1%57.6K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Deschatelets PascalChief Scientific Officer | SSale | −750 | $29.96 | −$22.5K | −0.1%1.14M after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Francois CedricChief Executive Officer | SSale | −6.01K | $29.96 | −$180.0K | −2.0%301.4K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Lewis KarenChief People Officer | SSale | −1.24K | $29.96 | −$37.2K | −2.8%43.9K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Nicholson NurChief Technical Officer | SSale | −2.15K | $29.96 | −$64.3K | −4.0%52.0K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Sullivan Timothy EugeneChief Financial Officer | SSale | −1.73K | $29.96 | −$51.8K | −2.0%86.4K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Townsend Adam J.Chief Commercial Officer | SSale | −2.20K | $29.96 | −$65.9K | −2.4%88.1K after | |
| Jan 21, 2025 (view filing) | Jan 17 | 4 days | Watson David O.General Counsel | SSale | −2.20K | $29.96 | −$65.9K | −2.0%105.6K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −1.10K | $30.43 | −$33.4K | −2.2%48.1K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −1.40K | $30.43 | −$42.5K | −1.6%84.7K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −3.95K | $30.43 | −$120.1K | −0.3%1.15M after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Eisele JeffreyChief Development Officer | SSale | −1.29K | $30.43 | −$39.3K | −2.3%55.6K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Francois CedricChief Executive Officer | SSale | −13.6K | $30.43 | −$412.4K | −3.1%418.5K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Lewis KarenChief People Officer | SSale | −1.75K | $30.43 | −$53.3K | −2.4%70.6K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Nicholson NurChief Technical Officer | SSale | −3.95K | $30.43 | −$120.1K | −4.5%84.5K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Sullivan Timothy EugeneChief Financial Officer | SSale | −3.09K | $30.43 | −$94.0K | −2.3%129.2K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −3.32K | $30.43 | −$101.1K | −3.8%84.7K after | |
| Jan 23, 2025 (view filing) | Jan 22 | 1 day | Watson David O.General Counsel | SSale | −3.32K | $30.43 | −$101.1K | −2.2%145.0K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −365 | $29.52 | −$10.8K | −0.4%84.3K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Francois CedricChief Executive Officer | SSale | −2.82K | $29.52 | −$83.4K | −0.7%415.7K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −826 | $29.52 | −$24.4K | −0.1%1.15M after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Eisele JeffreyChief Development Officer | SSale | −278 | $29.52 | −$8.21K | −0.5%55.3K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Lewis KarenChief People Officer | SSale | −364 | $29.52 | −$10.7K | −0.5%70.3K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Nicholson NurChief Technical Officer | SSale | −825 | $29.52 | −$24.4K | −1.0%83.7K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Sullivan Timothy EugeneChief Financial Officer | SSale | −546 | $29.52 | −$16.1K | −0.4%128.7K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −695 | $29.52 | −$20.5K | −0.8%84.0K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Watson David O.General Counsel | SSale | −695 | $29.52 | −$20.5K | −0.5%144.3K after | |
| Feb 12, 2025 (view filing) | Feb 11 | 1 day | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −363 | $28.54 | −$10.4K | −0.4%83.9K after | |
| Mar 6, 2025 (view filing) | Mar 5 | 1 day | Watson David O.General Counsel | SSale | −5.57K | $25.10 | −$139.8K | −3.9%138.7K after | |
| Mar 18, 2025 (view filing) | Mar 17 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −183 | $24.82 | −$4.54K | −0.4%48.0K after | |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Watson David O.General Counsel | SSale | −5.00K | $18.77 | −$93.8K | −3.6%133.7K after | 10b5-1 |
| Jul 16, 2025 (view filing) | Jul 14-15 | 2 days | Francois CedricChief Executive Officer | SSale | −139.4K | $20.19 | −$2.81M | −28.9%342.3K after | 2 lots10b5-1 |